Antiretroviral activity of protease inhibitors against Toxoplasma gondii
Related Experiment Video
Updated: May 15, 2026

Determination of Chemical Inhibitor Efficiency against Intracellular Toxoplasma Gondii Growth Using a Luciferase-Based Growth Assay
Published on: April 29, 2020
Lianet Monzote1, Marta Rodríguez, Yenisey Alfonso
1Parasitology Department, Institute of Tropical Medicine Pedro Kouri, Havana, Cuba.
Abstract:
The introduction of highly active antiretroviral therapy (HAART) has caused a marked reduction in the occurrence and severity of parasitic infections, including the toxoplasmic encephalitis (TE). These changes have been attributed to the restoration of cell-mediated immunity. This study was developed to examine the activity of six antiretroviral protease inhibitors (API) on Toxoplasma gondii tachyzoites. The six API showed anti-Toxoplasma activity, with IC50 value between 1.4 and 6.6 µg/mL. Further studies at the molecular level should be performed to clarify if the use of API could be beneficial or not for AIDS patients with TE.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Retroviruses
Retrovirus Life Cycles
